Stocks Which Saw Increased Insider Transactions: $QRHC $CERC $APEN

The Market Signal was created as a platform to help investors, if you own (NASDAQ:QRHC), (NASDAQ:CERC) or (NASDAQ:APEN) and want to join the fastest growing community of investors on the web then sign up to the link below. Members get free access to the best investment tools in the world. Start trading like a pro today. This is a limited time offer so click the link below NOW.

(Click link above or copy, paste and hit enter in your browser for your report)

Quest Resource: Insiders Affirm Long-Term Prospects

(Click link above or copy, paste and hit enter in your browser for your report)

Quest Resource Holding Corp (NASDAQ:QRHC) has bounced back after coming under pressure in the first half of the year, owing to the COVID-19 pandemic. The stock has erased a good chunk of the losses as a spike in insider transactions continues to trigger renewed investor interest.

Over the past six months, insider transactions in the stock has increased by more than 400% affirming growing confidence about the company's long term prospects among managers. The company is fresh from reporting second-quarter earnings, whereby revenues were down 13.7% to $22 million as gross profit dropped 7.9% to $4.4 million.

In response to the COVID-19 pandemic, Quest Resources has adapted quickly, opting to work closely with customers to ensure high levels of service while focusing on staff's health and safety.

Cerecor Insiders Jostle For Positions Amis Clinical Trials Optimism

(Click link above or copy, paste and hit enter in your browser for your report)

Cerecor Inc. (NASDAQ:CERC) insider activity has been building as insiders react to progress made in the advancement of the company's pipeline, including potential treatment for COVID-19. Over the past six months, insider transactions has surged 400%, affirming management strong belief about the company's growth metrics and long term prospects.

The biopharmaceutical company is coming off an impressive second quarter whereby it achieved significant milestones. Top on the list is the inking of a partnership with Myriad Genetics. The company also enrolled the first patient into its CERC-002 proof-concept as it continues to evaluate safety and efficacy with COVI-19 induced ARDS.

The company end ended the quarter with $45.4 million in cash sufficient to oversee various activities, including research and development expenses.

Apollo Endosurgery Turns To Cost Reductions To Bolster Bottom Line

(Click link above or copy, paste and hit enter in your browser for your report)

Apollo Endosurgery Inc. (NASDAQ:APEN) Insider activity continued to build up in the past six months even as the leader in invasive medical devices continued to face its biggest challenge owing to the COVID-19 pandemic. Insider transactions were up 404.68%, indicating managers remain confident about the company's long term prospects in the aftermath of the pandemic.

The company is coming off a disappointing second-quarter, whereby revenues dropped 60% to $5.6 million due to a sharp decline in healthcare utilization. In response, the company has implemented a number of cost reduction initiatives. It has also completed a $25 million equity financing highly needed to support operations going forward.

A recovery from the pandemic is already heating up with Apollo Endosurgery reporting a 90% increase in product sales in June. Sales in direct markets continue to beat estimates as well as sales from last year.

Please email or contact us for any edits or errors relating to this stock market news.

If you would like information on using our press release distribution service aimed at helping investors with the best stocks to buy and how to create your own stock portfolio. We cover the US Stock Market, Canadian Stock Market, the Australian Stock Market and other Stock Market news.

We will get back to you within 24 hours.


comtex tracking


Is there a problem with this press release? Contact the source provider Comtex at